Overview

Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Status:
Not yet recruiting

Trial end date:
2026-07-31

Target enrollment:

Participant gender:

Summary

This multicenter, randomized, controlled, open-label, prospective clinical trial was designed to evaluate the efficacy and safety of doxorubicin hydrochloride liposome injection in combination with irinotican (AI regimen) versus VIT regimen in the treatment of first relapsed and refractory pediatric rhabdomyosarcoma.

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Doxorubicin
Irinotecan
Liposomal doxorubicin
Temozolomide
Vincristine